NEW YORK – Dutch diagnostics company SkylineDx announced on Tuesday a partnership with the multiple myeloma department of Wuerzburg University Medical Center II in Germany to assess the company's MMprofiler diagnostic test.
The MMprofiler test is a microarray-based, gene-expression test for multiple myeloma based on a 92-gene signature called SKY92 for diagnosing patients in high and standard risk groups. The test runs on Thermo Fisher Scientific Affymetrix microarrays and is offered as a CE-IVD kit in Europe, and as a laboratory-developed test in the US.